Next Article in Journal
Fenarimol, a Pyrimidine-Type Fungicide, Inhibits Brassinosteroid Biosynthesis
Next Article in Special Issue
Atherosclerotic Calcification Detection: A Comparative Study of Carotid Ultrasound and Cone Beam CT
Previous Article in Journal
Mapping of Powdery Mildew Resistance Gene pmCH89 in a Putative Wheat-Thinopyrum intermedium Introgression Line
Previous Article in Special Issue
Meta-Analysis of miR-146a Polymorphisms Association with Coronary Artery Diseases and Ischemic Stroke
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview

Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL

Key Research Center of Liver Regulation for Hyperlipemia SATCM/Class III, Laboratory of Metabolism SATCM, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China
Inorganic Chemistry Laboratory, University of Oxford, South Parks Road, Oxford OX1 3QR, UK
Guangzhou Boxabio Ltd., D-106 Guangzhou International Business Incubator, Guangzhou 510530, China
Authors to whom correspondence should be addressed.
Academic Editor: Michael Henein
Int. J. Mol. Sci. 2015, 16(8), 17245-17272;
Received: 23 April 2015 / Revised: 26 June 2015 / Accepted: 16 July 2015 / Published: 28 July 2015
(This article belongs to the Special Issue Atherosclerosis and Vascular Imaging)
PDF [953 KB, uploaded 28 July 2015]


The hypothesis that raising high-density lipoprotein cholesterol (HDL-C) levels could improve the risk for cardiovascular disease (CVD) is facing challenges. There is multitudinous clear clinical evidence that the latest failures of HDL-C-raising drugs show no clear association with risks for CVD. At the genetic level, recent research indicates that steady-state HDL-C concentrations may provide limited information regarding the potential antiatherogenic functions of HDL. It is evident that the newer strategies may replace therapeutic approaches to simply raise plasma HDL-C levels. There is an urgent need to identify an efficient biomarker that accurately predicts the increased risk of atherosclerosis (AS) in patients and that may be used for exploring newer therapeutic targets. Studies from recent decades show that the composition, structure and function of circulating HDL are closely associated with high cardiovascular risk. A vast amount of data demonstrates that the most important mechanism through which HDL antagonizes AS involves the reverse cholesterol transport (RCT) process. Clinical trials of drugs that specifically target HDL have so far proven disappointing, so it is necessary to carry out review on the HDL therapeutics. View Full-Text
Keywords: HDL; biomarker; HDL function; reverse cholesterol transport; HDL therapies HDL; biomarker; HDL function; reverse cholesterol transport; HDL therapies

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Cao, P.; Pan, H.; Xiao, T.; Zhou, T.; Guo, J.; Su, Z. Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. Int. J. Mol. Sci. 2015, 16, 17245-17272.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top